In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica
BeiGene may have made its rep as a PD-1 pioneer in China, but it’s coming to the US with more cancer drugs in its arsenal.
The biotech $BGNE says its Bruton’s tyrosine kinase (BTK) inhibitor, zanubrutinib, now enjoys breakthrough status granted by the FDA — specifically, in the treatment of adult patients with mantle cell lymphoma who have been treated with at least one prior therapy.
It’s the first cancer therapy from mainland China to receive this endorsement, BeiGene president and general manager of China Xiaobing Wu told BioCentury.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
